Earnings Call Summary | The Oncology Institute(TOI.US) Q1 2024 Earnings Conference
Earnings Call Summary | The Oncology Institute(TOI.US) Q1 2024 Earnings Conference
The following is a summary of the The Oncology Institute, Inc. (TOI) Q1 2024 Earnings Call Transcript:
以下是腫瘤學研究所（TOI）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
The Oncology Institute's revenue for Q1 2024 grew by 24% YoY driven by a 64% increase in oral drug revenue.
The first quarter was marked by record prescription sales and revenue through its dispensaries and pharmacy with over 4,500 fills, contributing over $39 million in revenue.
Consolidated revenue for Q1 2024 was $94.7 million, while the gross profit stood at $11.97 million.
Operational losses increased due to compressing drug margins.
受口服藥物收入增長64％的推動，腫瘤研究所2024年第一季度的收入同比增長24％。
第一季度處方藥銷售和藥房收入創歷史新高，配藥量超過4500次，收入超過3,900萬美元。
2024年第一季度的合併收入爲9,470萬美元，毛利爲1197萬美元。
由於藥品利潤率的壓縮，運營損失增加。
Business Progress:
業務進展：
TOI signed seven new capitation and value-based contracts across three states contributing to growth.
The company network grew with the addition of seven new clinicians and two new clinics in South Florida.
Strategic changes are planned for procurement procedures to improve drug margins and control costs.
Expansion into the Oregon market is in the pipeline through new contracts for Q4.
A new Chief Development Officer was appointed to oversee growth initiatives.
TOI在三個州簽署了七份新的人均和基於價值的合同，爲增長做出了貢獻。
隨着南佛羅里達州新增七名臨床醫生和兩家新診所，公司網絡不斷壯大。
計劃對採購程序進行戰略調整，以提高藥品利潤率和控制成本。
通過第四季度的新合同，正在向俄勒岡州市場擴張。
任命了一位新的首席開發官來監督增長計劃。
More details: The Oncology Institute IR
更多詳情： 腫瘤研究所 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。